SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.3333.

A number of equities research analysts recently commented on SABS shares. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. Leerink Partners started coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 target price for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday. Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, November 17th. Finally, Wall Street Zen raised shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter worth $32,000. Virtu Financial LLC bought a new position in SAB Biotherapeutics in the third quarter valued at $40,000. HB Wealth Management LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $618,000. Finally, Woodline Partners LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $5,730,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Up 1.6%

Shares of NASDAQ:SABS opened at $3.70 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50. The stock has a market cap of $176.16 million, a price-to-earnings ratio of -1.20 and a beta of 0.58. The company has a 50 day moving average of $3.00 and a 200-day moving average of $2.42. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38. On average, sell-side analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.